Vidaza (azacitidine) Disease Interactions
There are 4 disease interactions with Vidaza (azacitidine):
Azacitidine (Includes Vidaza) ↔ Hepatic Tumors
Severe Potential Hazard, Moderate plausibility
Applies to: Hepatic Tumor
The use of azacitidine injection is contraindicated in patients with advanced malignant hepatic tumors.
Azacitidine (Includes Vidaza) ↔ Hepatic Impairment
Moderate Potential Hazard, Moderate plausibility
Applies to: Liver Disease
Azacitidine is potentially hepatotoxic in patients with preexisting hepatic impairment and caution should be exercised when prescribing in patients with liver disease.
Azacitidine (Includes Vidaza) ↔ Renal Impairment
Moderate Potential Hazard, Moderate plausibility
Applies to: Renal Dysfunction
Patients with renal impairment may be at increased risk of renal toxicity when using azacitidine. This drug is primarily excreted by the kidneys. Therefore, these patients should be closely monitored for toxicity.
Miscellaneous Antineoplastics (Includes Vidaza) ↔ Anemia
Moderate Potential Hazard, Moderate plausibility
Applies to: Anemia, Neutropenia, Thrombocytopenia
Some miscellaneous antineoplastics such as azacitidine and lenalidomide cause anemia, neutropenia, and thrombocytopenia. Patients with these preexisting conditions should be monitored carefully. Monitor complete blood counts frequently for response and/or toxicity, at a minimum, prior to each dosing cycle.
Vidaza (azacitidine) drug Interactions
There are 117 drug interactions with Vidaza (azacitidine)
See also...
Drug Interaction Classification
The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
